Idaho Tech Preparing for Regulatory Clearance, Launch of Blood Culture ID, GI Panels | GenomeWeb

NEW YORK (GenomeWeb News) – Idaho Technology today said that it anticipates commercially launching its blood culture ID and gastrointestinal panels by early 2014.

In an update on the company's clinical pipeline, Idaho Technology CEO Kirk Ririe said that clinical trials for the BCID panel have begun while the clinical evaluation of the GI panel is expected to launch in the first quarter of 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.